Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.
about
Meningococcal B vaccine and the vision of a meningitis free worldEnter B and W: two new meningococcal vaccine programmes launchedVaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysisMeningococcal B Vaccination (4CMenB) in Infants and ToddlersMeningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other PurposesHow the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis VaccinesPrevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infectionHealth and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programmeEmerging experience with meningococcal serogroup B protein vaccines.Recent Progress in the Prevention of Serogroup B Meningococcal Disease.Does post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility?Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccinePhase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage.Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal.Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.Hierarchical genomic analysis of carried and invasive serogroup A Neisseria meningitidis during the 2011 epidemic in Chad.Acceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: a survey.Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development.Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis.A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).Bexsero® chronicle.In-hospital management of children with bacterial meningitis in Italy.Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibodyNeisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011.An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands.Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern SpainPrevalence and phase variable expression status of two autotransporters, NalP and MspA, in carriage and disease isolates of Neisseria meningitidis.Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.The distribution and 'in vivo' phase variation status of haemoglobin receptors in invasive meningococcal serogroup B disease: genotypic and phenotypic analysis.Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.Identification and therapeutic potential of a vitronectin binding region of meningococcal msfThe impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission.Molecular Engineering of Ghfp, the Gonococcal Orthologue of Neisseria meningitidis Factor H Binding Protein.Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort studyMeningococcal vaccine antigen diversity in global databases.Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European CountriesEstimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine IntroductionTemporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccinesVaccine Potential and Diversity of the Putative Cell Binding Factor (CBF, NMB0345/NEIS1825) Protein of Neisseria meningitidis.
P2860
Q26770696-A47EDFF3-C3C0-4690-936D-5115D448EE85Q26775667-91081704-E21F-402F-B84B-A2F308D87123Q26779489-C2F58D08-20D8-49DE-B4D9-C046263D13E6Q26782285-0E43423C-AE6F-4EC7-B9A3-1067BFAF3C57Q26782318-E34AD8FF-FBAD-4451-9FA9-81E03CB60C7EQ26782340-61F1E08A-A811-48B4-9E52-19B1C02185E5Q28080522-1CB26AF3-ABAF-4CE8-B384-903C900DB67AQ28391723-36F26408-3832-4DD0-88EF-0F30595953B5Q30234958-E9CAE136-C9A4-4590-BBFA-CD50AA89588AQ30235040-82ADFAF5-F1B8-487C-9A82-9ED4CBC34E20Q30235138-5D17A032-25DD-4FE8-BF73-101CA2C98C0AQ33600936-BFFFADCE-9B61-41CC-A97D-620ED774A3DFQ33603065-E7475B91-9225-4D25-97C0-CD2644B7D609Q33620864-AFF8D0EF-4DE7-4E08-9057-0FD46DE58B5FQ33703560-511F7800-18D5-4034-B668-206B90135564Q33717336-6142B227-8355-400C-AB24-7F0EC3B31AC7Q33723468-5F453163-CEFA-4DA5-B280-9C992FD4E516Q33743483-4081D1C2-2918-4527-B136-62F1B0DE45F2Q34231871-56ECFCE8-33ED-425B-B919-3126873D36E5Q34291050-8501A2CE-7666-4DDE-B3D3-5F7735912F93Q34562726-C132DAC5-B0AD-4D45-8DD5-955E8ACFBE7AQ34587235-21EFA3E8-2CB7-4CFA-B535-4FF6171108D2Q34661129-58CF920B-1B26-4F95-9B34-8ACDA2F880CDQ34700648-8CA8055D-D710-4524-9B10-8C0B04B1D2ECQ34746633-C8EA0BD3-2D0B-4F79-A599-83FA944415F2Q34776964-7319887C-5610-4A2D-B6C7-FD00E3263437Q34921091-0509318C-CBBC-4C27-B9ED-EA7844B213CFQ34955474-BCDF0135-086E-4D3C-856E-D1DB922EFE45Q35010428-C8B00F13-3238-44C4-BBD2-2E35EEAFEAF6Q35187629-8C27A03C-FDFD-47DC-B686-4E378CB48E61Q35235006-630FAB77-6789-4141-8549-3FB165DF2F47Q35724206-7BD5113C-5574-47A6-A317-ABE7A17326E1Q35773926-43F586FD-9A88-4BD6-A634-5CDC88EC26DFQ35826786-DE90CD7D-ED87-4346-9C58-CDCB8D56FC0DQ35871107-138D56D2-29E4-4205-8C8F-8B1CD5F6D02DQ35947795-5EFF85F6-6118-46E9-B67E-C9B477CD2680Q36006680-2E04F1A1-2185-482F-87AF-DF024AD5868CQ36064003-B1B08D3F-79AC-453C-A70F-BD54EC221B7BQ36065267-99372A21-174D-476B-88FD-30637E74CDA6Q36098758-9EB6015B-E8DB-4368-B2F7-EDF79B8C5D44
P2860
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Predicted strain coverage of a ...... e and quantitative assessment.
@en
Predicted strain coverage of a meningococcal multicomponent vaccine
@nl
type
label
Predicted strain coverage of a ...... e and quantitative assessment.
@en
Predicted strain coverage of a meningococcal multicomponent vaccine
@nl
prefLabel
Predicted strain coverage of a ...... e and quantitative assessment.
@en
Predicted strain coverage of a meningococcal multicomponent vaccine
@nl
P2093
P50
P1476
Predicted strain coverage of a ...... e and quantitative assessment.
@en
P2093
Ala Eddine Deghmane
Alessandro Muzzi
Anna Carannante
Cecilia Fazio
Danielle Thompson
Davide Serruto
Dominique A Caugant
Fabio Rigat
Giacomo Frosi
P304
P356
10.1016/S1473-3099(13)70006-9
P577
2013-02-13T00:00:00Z